Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P41159
UPID:
LEP_HUMAN
Alternative names:
Obese protein; Obesity factor
Alternative UPACC:
P41159; O15158; Q56A88
Background:
Leptin, known as the obesity factor, plays a crucial role in regulating energy balance and body weight. It acts on the brain to decrease food intake and increase energy expenditure. Additionally, leptin influences various physiological processes including reproductive function, immune response, and glucose metabolism.
Therapeutic significance:
Leptin deficiency, a rare disease characterized by severe obesity and hyperphagia, underscores the protein's potential as a therapeutic target. Understanding leptin's mechanisms offers promising avenues for treating obesity and related metabolic disorders.